Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q3 FY2025 Earnings Presentation
21 slides from Aurobindo Pharma's earnings presentation, Feb 6, 2025
Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
February 6, 2025 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q3FY25
Aurobindo Pharma Limited Earnings Presentation Q3FY25
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q3FY25 Business & Financial Highlights Update on Biosimilars, Peptides, 11 Vaccines and CMO space 14 Financial Summary 13 17 Filings Snapshot 3
Slide 5: Q3FY25 Business & Financial Highlights
Q3FY25 Business & Financial Highlights 4
Slide 6: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q2FY25 ₹ 7,796 Cr ₹ 1,566 Cr ₹ 817 Cr Q-o-Q growth % 2.3% 3.9% 3.5% 5
Slide 7: Business Highlights – Q3FY25
Business Highlights – Q3FY25 Highest ever quarterly revenue with 8.5% growth YoY (excluding transient product ~12% YoY) EBITDA margins stood at comfortable levels of 20.4%, after absorbing higher R&D cost of ~₹ 50 Cr YoY & lower transient product sales Net Capex of US$ 106 million* primarily towards
Slide 8: Quarterly Performance – Q3FY25
Quarterly Performance – Q3FY25 Revenue (₹ Crore) US Revenue excluding Puerto Rico (US$ Mn) 451 7,979 7,796 432 435 426 7,580 7,567 421 7,352 7,219 409 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 EBITDA (₹ Crore) Net Debt to Equity 1,601 1,687 0.04 1,620 1,566
Slide 9: Consolidated Business Performance
Consolidated Business Performance ₹ Crores Q3FY25 Q3FY24 Y-o-Y (%) Q2FY25 Q-o-Q (%) USA** 3,671 3,756 -2.3% 3,530 4.0% Europe 2,121 1,728 22.7% 2,105 0.8% Growth Markets* 873 627 39.3% 812 7.6% ARV 307 179 71.2% 193 59.1% Total Formulations 6,973 6,291 10.8% 6,640 5.0% Beta-lactam 722 737 -2.0% 837
Slide 10: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 460 451 435 440 421 420 • US revenue in Q3FY25 decreased by 3.7% YoY and increased by 400 380 3.1% QoQ to USD 435 Mn, accounting for 46.0% of 360 340 consolidated revenue 320 300 • Specialty & Injecta
Slide 11: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crore) 1,156 236 229 104 1,022 1,006 193 97 75 36 22 23 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Growth Markets posted revenue of US$ Europe business posted revenue of
Slide 12: Update on Biosimilars, Peptides, Vaccines and CMO space
Update on Biosimilars, Peptides, Vaccines and CMO space 11
Slide 13: Continuing to advance our efforts in biosimilars, peptides, vaccines and CMO space
Continuing to advance our efforts in biosimilars, peptides, vaccines and CMO space Biosimilars CMO Peptides and Vaccines • Advancing our second wave of oncology and • The civil works have commenced for our • 14 DMFs filed in peptides immunology biosimilars large-scale CMO facility for mammalian • Ex
Slide 14: Biosimilars pipeline update
Biosimilars pipeline update Key Products Therapy Current Status (mkt size in USD Bn) Segment • Phase 1 PK/PD clinical study completed. Multi center and multi country Phase 3 study BP01 (6.2 bn) Oncology in NSCLC patients is in progress BP13 (1.5 bn) Oncology • Received positive opinion from European
Slide 15: Financial Summary
Financial Summary 14
Slide 16: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement ₹ Cr Q3FY25 Q3FY24 YoY Chg. (%) Q2FY25 QoQ Chg. (%) Revenue from Operations 7,979 7,352 8.5% 7,796 2.3% Gross Profit 4,663 4,201 11.0% 4,586 1.7% Gross Margin 58.4% 57.1% 130 bps 58.8% -38 bps Overheads -3,036 -2,600 16.8% -3,020 0.5% EBITDA (before Forex
Slide 17: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-21 Mar-22 Mar-23 Mar-24 Dec-24 Closing Rate (INR/USD) 73.110 75.793 82.170 83.405 85.620 592 752 815 758 833 966 963 Fx Loan restated in INR 4,929 2,223 4,638 3,994 6,568 Rupee Loan 44 150 224 2,324 1,677 232 228 196 Gross Debt 4,972 2,373 4,8
Slide 18: Filing Snapshot
Filing Snapshot 17
Slide 19: US ANDA Filings Snapshot as on 31st December 2024
US ANDA Filings Snapshot as on 31st December 2024 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 154 27.7 Aurobindo (Excl. Specialty & 800 678 508 600 Specialty & Injectables 300 700 ARV 29 0.3 600 500 250 500 200 170 Injectables) 400 400 150 48.7 300 300 149 CVS 123 200 200 119 10
Slide 20: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at Mar As at Category Geography Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 24 Dec 24 US* 429 478 541 586 639 727 774 830 853 Europe** 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,642 3,851 Formulations SA** 401 415 43
Slide 21: Thank You
Thank You For more information, contact: ir@aurobindo.com; cc@aurobindo.com Investor Relations | Corporate Communications Digitally signed by BADDIGAM www.aurobindo.com +91 40 6672 1551 | 6672 5005 ADI REDDY Date: 2025.02.06 19:40:41 +05'30' 20